Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

GeneDx Holdings (WGS) Non Operating Income (2020 - 2026)

GeneDx Holdings has reported Non Operating Income over the past 7 years, most recently at -$4.9 million for Q1 2026.

  • Quarterly Non Operating Income fell 223.19% to -$4.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$15.8 million through Mar 2026, up 20.46% year-over-year, with the annual reading at -$8.1 million for FY2025, 38.07% up from the prior year.
  • Non Operating Income was -$4.9 million for Q1 2026 at GeneDx Holdings, up from -$8.3 million in the prior quarter.
  • Over five years, Non Operating Income peaked at $27.8 million in Q2 2022 and troughed at -$18.8 million in Q2 2024.
  • The 5-year median for Non Operating Income is -$269500.0 (2022), against an average of $594125.0.
  • Year-over-year, Non Operating Income skyrocketed 4003.23% in 2022 and then crashed 56800.0% in 2023.
  • A 5-year view of Non Operating Income shows it stood at $16.2 million in 2022, then plummeted by 103.34% to -$541000.0 in 2023, then tumbled by 31.98% to -$714000.0 in 2024, then plummeted by 1067.23% to -$8.3 million in 2025, then soared by 40.63% to -$4.9 million in 2026.
  • Per Business Quant, the three most recent readings for WGS's Non Operating Income are -$4.9 million (Q1 2026), -$8.3 million (Q4 2025), and -$4.1 million (Q3 2025).